The global Peripheral T-cell lymphoma Therapy market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.

The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report aims to provide a comprehensive presentation of the global market for Peripheral T-cell lymphoma Therapy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Peripheral T-cell lymphoma Therapy.

Report Scope

The Peripheral T-cell lymphoma Therapy market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Peripheral T-cell lymphoma Therapy market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Peripheral T-cell lymphoma Therapy companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Peripheral T-cell lymphoma Therapy Market Report

Report Metric	Details
Report Name	Peripheral T-cell lymphoma Therapy Market
CAGR	5%
Segment by Type	Chidamide Selinexor Other
Segment by Application	Hospitals Clinics
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Antengene, Genor BioPharma Co., Ltd., Hospira (Pfizer Inc.), Dizal Pharma, Bristol-Myers Squibb Company, Sigma-Tau Pharmaceuticals, Inc., Pacira Pharmaceuticals, Inc., Spectrum Pharmaceuticals, Inc., Celgene Corporation, Eisai Co., Ltd., Leadiant Biosciences, Merck, Genmab AS, HUYABIO International
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Peripheral T-cell lymphoma Therapy companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Peripheral T-cell lymphoma Therapy Market report?

Ans: The main players in the Peripheral T-cell lymphoma Therapy Market are Antengene, Genor BioPharma Co., Ltd., Hospira (Pfizer Inc.), Dizal Pharma, Bristol-Myers Squibb Company, Sigma-Tau Pharmaceuticals, Inc., Pacira Pharmaceuticals, Inc., Spectrum Pharmaceuticals, Inc., Celgene Corporation, Eisai Co., Ltd., Leadiant Biosciences, Merck, Genmab AS, HUYABIO International

What are the Application segmentation covered in the Peripheral T-cell lymphoma Therapy Market report?

Ans: The Applications covered in the Peripheral T-cell lymphoma Therapy Market report are Hospitals, Clinics

What are the Type segmentation covered in the Peripheral T-cell lymphoma Therapy Market report?

Ans: The Types covered in the Peripheral T-cell lymphoma Therapy Market report are Chidamide, Selinexor, Other

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Peripheral T-cell lymphoma Therapy Market Size Growth Rate by Type: 2019 VS 2023 VS 2030

1.2.2 Chidamide

1.2.3 Selinexor

1.2.4 Other

1.3 Market by Application

1.3.1 Global Peripheral T-cell lymphoma Therapy Market Growth by Application: 2019 VS 2023 VS 2030

1.3.2 Hospitals

1.3.3 Clinics

1.4 Study Objectives

1.5 Years Considered

1.6 Years Considered

2 Global Growth Trends

2.1 Global Peripheral T-cell lymphoma Therapy Market Perspective (2019-2030)

2.2 Peripheral T-cell lymphoma Therapy Growth Trends by Region

2.2.1 Global Peripheral T-cell lymphoma Therapy Market Size by Region: 2019 VS 2023 VS 2030

2.2.2 Peripheral T-cell lymphoma Therapy Historic Market Size by Region (2019-2024)

2.2.3 Peripheral T-cell lymphoma Therapy Forecasted Market Size by Region (2025-2030)

2.3 Peripheral T-cell lymphoma Therapy Market Dynamics

2.3.1 Peripheral T-cell lymphoma Therapy Industry Trends

2.3.2 Peripheral T-cell lymphoma Therapy Market Drivers

2.3.3 Peripheral T-cell lymphoma Therapy Market Challenges

2.3.4 Peripheral T-cell lymphoma Therapy Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Peripheral T-cell lymphoma Therapy Players by Revenue

3.1.1 Global Top Peripheral T-cell lymphoma Therapy Players by Revenue (2019-2024)

3.1.2 Global Peripheral T-cell lymphoma Therapy Revenue Market Share by Players (2019-2024)

3.2 Global Peripheral T-cell lymphoma Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Players Covered: Ranking by Peripheral T-cell lymphoma Therapy Revenue

3.4 Global Peripheral T-cell lymphoma Therapy Market Concentration Ratio

3.4.1 Global Peripheral T-cell lymphoma Therapy Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Peripheral T-cell lymphoma Therapy Revenue in 2023

3.5 Peripheral T-cell lymphoma Therapy Key Players Head office and Area Served

3.6 Key Players Peripheral T-cell lymphoma Therapy Product Solution and Service

3.7 Date of Enter into Peripheral T-cell lymphoma Therapy Market

3.8 Mergers & Acquisitions, Expansion Plans

4 Peripheral T-cell lymphoma Therapy Breakdown Data by Type

4.1 Global Peripheral T-cell lymphoma Therapy Historic Market Size by Type (2019-2024)

4.2 Global Peripheral T-cell lymphoma Therapy Forecasted Market Size by Type (2025-2030)

5 Peripheral T-cell lymphoma Therapy Breakdown Data by Application

5.1 Global Peripheral T-cell lymphoma Therapy Historic Market Size by Application (2019-2024)

5.2 Global Peripheral T-cell lymphoma Therapy Forecasted Market Size by Application (2025-2030)

6 North America

6.1 North America Peripheral T-cell lymphoma Therapy Market Size (2019-2030)

6.2 North America Peripheral T-cell lymphoma Therapy Market Growth Rate by Country: 2019 VS 2023 VS 2030

6.3 North America Peripheral T-cell lymphoma Therapy Market Size by Country (2019-2024)

6.4 North America Peripheral T-cell lymphoma Therapy Market Size by Country (2025-2030)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Peripheral T-cell lymphoma Therapy Market Size (2019-2030)

7.2 Europe Peripheral T-cell lymphoma Therapy Market Growth Rate by Country: 2019 VS 2023 VS 2030

7.3 Europe Peripheral T-cell lymphoma Therapy Market Size by Country (2019-2024)

7.4 Europe Peripheral T-cell lymphoma Therapy Market Size by Country (2025-2030)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Peripheral T-cell lymphoma Therapy Market Size (2019-2030)

8.2 Asia-Pacific Peripheral T-cell lymphoma Therapy Market Growth Rate by Region: 2019 VS 2023 VS 2030

8.3 Asia-Pacific Peripheral T-cell lymphoma Therapy Market Size by Region (2019-2024)

8.4 Asia-Pacific Peripheral T-cell lymphoma Therapy Market Size by Region (2025-2030)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Peripheral T-cell lymphoma Therapy Market Size (2019-2030)

9.2 Latin America Peripheral T-cell lymphoma Therapy Market Growth Rate by Country: 2019 VS 2023 VS 2030

9.3 Latin America Peripheral T-cell lymphoma Therapy Market Size by Country (2019-2024)

9.4 Latin America Peripheral T-cell lymphoma Therapy Market Size by Country (2025-2030)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Peripheral T-cell lymphoma Therapy Market Size (2019-2030)

10.2 Middle East & Africa Peripheral T-cell lymphoma Therapy Market Growth Rate by Country: 2019 VS 2023 VS 2030

10.3 Middle East & Africa Peripheral T-cell lymphoma Therapy Market Size by Country (2019-2024)

10.4 Middle East & Africa Peripheral T-cell lymphoma Therapy Market Size by Country (2025-2030)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Antengene

11.1.1 Antengene Company Detail

11.1.2 Antengene Business Overview

11.1.3 Antengene Peripheral T-cell lymphoma Therapy Introduction

11.1.4 Antengene Revenue in Peripheral T-cell lymphoma Therapy Business (2019-2024)

11.1.5 Antengene Recent Development

11.2 Genor BioPharma Co., Ltd.

11.2.1 Genor BioPharma Co., Ltd. Company Detail

11.2.2 Genor BioPharma Co., Ltd. Business Overview

11.2.3 Genor BioPharma Co., Ltd. Peripheral T-cell lymphoma Therapy Introduction

11.2.4 Genor BioPharma Co., Ltd. Revenue in Peripheral T-cell lymphoma Therapy Business (2019-2024)

11.2.5 Genor BioPharma Co., Ltd. Recent Development

11.3 Hospira (Pfizer Inc.)

11.3.1 Hospira (Pfizer Inc.) Company Detail

11.3.2 Hospira (Pfizer Inc.) Business Overview

11.3.3 Hospira (Pfizer Inc.) Peripheral T-cell lymphoma Therapy Introduction

11.3.4 Hospira (Pfizer Inc.) Revenue in Peripheral T-cell lymphoma Therapy Business (2019-2024)

11.3.5 Hospira (Pfizer Inc.) Recent Development

11.4 Dizal Pharma

11.4.1 Dizal Pharma Company Detail

11.4.2 Dizal Pharma Business Overview

11.4.3 Dizal Pharma Peripheral T-cell lymphoma Therapy Introduction

11.4.4 Dizal Pharma Revenue in Peripheral T-cell lymphoma Therapy Business (2019-2024)

11.4.5 Dizal Pharma Recent Development

11.5 Bristol-Myers Squibb Company

11.5.1 Bristol-Myers Squibb Company Company Detail

11.5.2 Bristol-Myers Squibb Company Business Overview

11.5.3 Bristol-Myers Squibb Company Peripheral T-cell lymphoma Therapy Introduction

11.5.4 Bristol-Myers Squibb Company Revenue in Peripheral T-cell lymphoma Therapy Business (2019-2024)

11.5.5 Bristol-Myers Squibb Company Recent Development

11.6 Sigma-Tau Pharmaceuticals, Inc.

11.6.1 Sigma-Tau Pharmaceuticals, Inc. Company Detail

11.6.2 Sigma-Tau Pharmaceuticals, Inc. Business Overview

11.6.3 Sigma-Tau Pharmaceuticals, Inc. Peripheral T-cell lymphoma Therapy Introduction

11.6.4 Sigma-Tau Pharmaceuticals, Inc. Revenue in Peripheral T-cell lymphoma Therapy Business (2019-2024)

11.6.5 Sigma-Tau Pharmaceuticals, Inc. Recent Development

11.7 Pacira Pharmaceuticals, Inc.

11.7.1 Pacira Pharmaceuticals, Inc. Company Detail

11.7.2 Pacira Pharmaceuticals, Inc. Business Overview

11.7.3 Pacira Pharmaceuticals, Inc. Peripheral T-cell lymphoma Therapy Introduction

11.7.4 Pacira Pharmaceuticals, Inc. Revenue in Peripheral T-cell lymphoma Therapy Business (2019-2024)

11.7.5 Pacira Pharmaceuticals, Inc. Recent Development

11.8 Spectrum Pharmaceuticals, Inc.

11.8.1 Spectrum Pharmaceuticals, Inc. Company Detail

11.8.2 Spectrum Pharmaceuticals, Inc. Business Overview

11.8.3 Spectrum Pharmaceuticals, Inc. Peripheral T-cell lymphoma Therapy Introduction

11.8.4 Spectrum Pharmaceuticals, Inc. Revenue in Peripheral T-cell lymphoma Therapy Business (2019-2024)

11.8.5 Spectrum Pharmaceuticals, Inc. Recent Development

11.9 Celgene Corporation

11.9.1 Celgene Corporation Company Detail

11.9.2 Celgene Corporation Business Overview

11.9.3 Celgene Corporation Peripheral T-cell lymphoma Therapy Introduction

11.9.4 Celgene Corporation Revenue in Peripheral T-cell lymphoma Therapy Business (2019-2024)

11.9.5 Celgene Corporation Recent Development

11.10 Eisai Co., Ltd.

11.10.1 Eisai Co., Ltd. Company Detail

11.10.2 Eisai Co., Ltd. Business Overview

11.10.3 Eisai Co., Ltd. Peripheral T-cell lymphoma Therapy Introduction

11.10.4 Eisai Co., Ltd. Revenue in Peripheral T-cell lymphoma Therapy Business (2019-2024)

11.10.5 Eisai Co., Ltd. Recent Development

11.11 Leadiant Biosciences

11.11.1 Leadiant Biosciences Company Detail

11.11.2 Leadiant Biosciences Business Overview

11.11.3 Leadiant Biosciences Peripheral T-cell lymphoma Therapy Introduction

11.11.4 Leadiant Biosciences Revenue in Peripheral T-cell lymphoma Therapy Business (2019-2024)

11.11.5 Leadiant Biosciences Recent Development

11.12 Merck

11.12.1 Merck Company Detail

11.12.2 Merck Business Overview

11.12.3 Merck Peripheral T-cell lymphoma Therapy Introduction

11.12.4 Merck Revenue in Peripheral T-cell lymphoma Therapy Business (2019-2024)

11.12.5 Merck Recent Development

11.13 Genmab AS

11.13.1 Genmab AS Company Detail

11.13.2 Genmab AS Business Overview

11.13.3 Genmab AS Peripheral T-cell lymphoma Therapy Introduction

11.13.4 Genmab AS Revenue in Peripheral T-cell lymphoma Therapy Business (2019-2024)

11.13.5 Genmab AS Recent Development

11.14 HUYABIO International

11.14.1 HUYABIO International Company Detail

11.14.2 HUYABIO International Business Overview

11.14.3 HUYABIO International Peripheral T-cell lymphoma Therapy Introduction

11.14.4 HUYABIO International Revenue in Peripheral T-cell lymphoma Therapy Business (2019-2024)

11.14.5 HUYABIO International Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Disclaimer

13.3 Author Details

FEATURED COMPANIES

Genor BioPharma Co Ltd

Hospira (Pfizer Inc.)

Bristol Myers Squibb Company

Sigma tau pharmaceuticals Inc.

Pacira Pharmaceuticals Inc

Spectrum Pharmaceuticals Inc

HUYABIO International

List of Tables

Table 1. Global Peripheral T-cell lymphoma Therapy Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030

Table 2. Key Players of Chidamide

Table 3. Key Players of Selinexor

Table 4. Key Players of Other

Table 5. Global Peripheral T-cell lymphoma Therapy Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030

Table 6. Global Peripheral T-cell lymphoma Therapy Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Table 7. Global Peripheral T-cell lymphoma Therapy Market Size by Region (2019-2024) & (US$ Million)

Table 8. Global Peripheral T-cell lymphoma Therapy Market Share by Region (2019-2024)

Table 9. Global Peripheral T-cell lymphoma Therapy Forecasted Market Size by Region (2025-2030) & (US$ Million)

Table 10. Global Peripheral T-cell lymphoma Therapy Market Share by Region (2025-2030)

Table 11. Peripheral T-cell lymphoma Therapy Market Trends

Table 12. Peripheral T-cell lymphoma Therapy Market Drivers

Table 13. Peripheral T-cell lymphoma Therapy Market Challenges

Table 14. Peripheral T-cell lymphoma Therapy Market Restraints

Table 15. Global Peripheral T-cell lymphoma Therapy Revenue by Players (2019-2024) & (US$ Million)

Table 16. Global Peripheral T-cell lymphoma Therapy Market Share by Players (2019-2024)

Table 17. Global Top Peripheral T-cell lymphoma Therapy Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Peripheral T-cell lymphoma Therapy as of 2023)

Table 18. Ranking of Global Top Peripheral T-cell lymphoma Therapy Companies by Revenue (US$ Million) in 2023

Table 19. Global 5 Largest Players Market Share by Peripheral T-cell lymphoma Therapy Revenue (CR5 and HHI) & (2019-2024)

Table 20. Key Players Headquarters and Area Served

Table 21. Key Players Peripheral T-cell lymphoma Therapy Product Solution and Service

Table 22. Date of Enter into Peripheral T-cell lymphoma Therapy Market

Table 23. Mergers & Acquisitions, Expansion Plans

Table 24. Global Peripheral T-cell lymphoma Therapy Market Size by Type (2019-2024) & (US$ Million)

Table 25. Global Peripheral T-cell lymphoma Therapy Revenue Market Share by Type (2019-2024)

Table 26. Global Peripheral T-cell lymphoma Therapy Forecasted Market Size by Type (2025-2030) & (US$ Million)

Table 27. Global Peripheral T-cell lymphoma Therapy Revenue Market Share by Type (2025-2030)

Table 28. Global Peripheral T-cell lymphoma Therapy Market Size by Application (2019-2024) & (US$ Million)

Table 29. Global Peripheral T-cell lymphoma Therapy Revenue Market Share by Application (2019-2024)

Table 30. Global Peripheral T-cell lymphoma Therapy Forecasted Market Size by Application (2025-2030) & (US$ Million)

Table 31. Global Peripheral T-cell lymphoma Therapy Revenue Market Share by Application (2025-2030)

Table 32. North America Peripheral T-cell lymphoma Therapy Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 33. North America Peripheral T-cell lymphoma Therapy Market Size by Country (2019-2024) & (US$ Million)

Table 34. North America Peripheral T-cell lymphoma Therapy Market Size by Country (2025-2030) & (US$ Million)

Table 35. Europe Peripheral T-cell lymphoma Therapy Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 36. Europe Peripheral T-cell lymphoma Therapy Market Size by Country (2019-2024) & (US$ Million)

Table 37. Europe Peripheral T-cell lymphoma Therapy Market Size by Country (2025-2030) & (US$ Million)

Table 38. Asia-Pacific Peripheral T-cell lymphoma Therapy Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030

Table 39. Asia-Pacific Peripheral T-cell lymphoma Therapy Market Size by Region (2019-2024) & (US$ Million)

Table 40. Asia-Pacific Peripheral T-cell lymphoma Therapy Market Size by Region (2025-2030) & (US$ Million)

Table 41. Latin America Peripheral T-cell lymphoma Therapy Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 42. Latin America Peripheral T-cell lymphoma Therapy Market Size by Country (2019-2024) & (US$ Million)

Table 43. Latin America Peripheral T-cell lymphoma Therapy Market Size by Country (2025-2030) & (US$ Million)

Table 44. Middle East & Africa Peripheral T-cell lymphoma Therapy Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 45. Middle East & Africa Peripheral T-cell lymphoma Therapy Market Size by Country (2019-2024) & (US$ Million)

Table 46. Middle East & Africa Peripheral T-cell lymphoma Therapy Market Size by Country (2025-2030) & (US$ Million)

Table 47. Antengene Company Detail

Table 48. Antengene Business Overview

Table 49. Antengene Peripheral T-cell lymphoma Therapy Product

Table 50. Antengene Revenue in Peripheral T-cell lymphoma Therapy Business (2019-2024) & (US$ Million)

Table 51. Antengene Recent Development

Table 52. Genor BioPharma Co., Ltd. Company Detail

Table 53. Genor BioPharma Co., Ltd. Business Overview

Table 54. Genor BioPharma Co., Ltd. Peripheral T-cell lymphoma Therapy Product

Table 55. Genor BioPharma Co., Ltd. Revenue in Peripheral T-cell lymphoma Therapy Business (2019-2024) & (US$ Million)

Table 56. Genor BioPharma Co., Ltd. Recent Development

Table 57. Hospira (Pfizer Inc.) Company Detail

Table 58. Hospira (Pfizer Inc.) Business Overview

Table 59. Hospira (Pfizer Inc.) Peripheral T-cell lymphoma Therapy Product

Table 60. Hospira (Pfizer Inc.) Revenue in Peripheral T-cell lymphoma Therapy Business (2019-2024) & (US$ Million)

Table 61. Hospira (Pfizer Inc.) Recent Development

Table 62. Dizal Pharma Company Detail

Table 63. Dizal Pharma Business Overview

Table 64. Dizal Pharma Peripheral T-cell lymphoma Therapy Product

Table 65. Dizal Pharma Revenue in Peripheral T-cell lymphoma Therapy Business (2019-2024) & (US$ Million)

Table 66. Dizal Pharma Recent Development

Table 67. Bristol-Myers Squibb Company Company Detail

Table 68. Bristol-Myers Squibb Company Business Overview

Table 69. Bristol-Myers Squibb Company Peripheral T-cell lymphoma Therapy Product

Table 70. Bristol-Myers Squibb Company Revenue in Peripheral T-cell lymphoma Therapy Business (2019-2024) & (US$ Million)

Table 71. Bristol-Myers Squibb Company Recent Development

Table 72. Sigma-Tau Pharmaceuticals, Inc. Company Detail

Table 73. Sigma-Tau Pharmaceuticals, Inc. Business Overview

Table 74. Sigma-Tau Pharmaceuticals, Inc. Peripheral T-cell lymphoma Therapy Product

Table 75. Sigma-Tau Pharmaceuticals, Inc. Revenue in Peripheral T-cell lymphoma Therapy Business (2019-2024) & (US$ Million)

Table 76. Sigma-Tau Pharmaceuticals, Inc. Recent Development

Table 77. Pacira Pharmaceuticals, Inc. Company Detail

Table 78. Pacira Pharmaceuticals, Inc. Business Overview

Table 79. Pacira Pharmaceuticals, Inc. Peripheral T-cell lymphoma Therapy Product

Table 80. Pacira Pharmaceuticals, Inc. Revenue in Peripheral T-cell lymphoma Therapy Business (2019-2024) & (US$ Million)

Table 81. Pacira Pharmaceuticals, Inc. Recent Development

Table 82. Spectrum Pharmaceuticals, Inc. Company Detail

Table 83. Spectrum Pharmaceuticals, Inc. Business Overview

Table 84. Spectrum Pharmaceuticals, Inc. Peripheral T-cell lymphoma Therapy Product

Table 85. Spectrum Pharmaceuticals, Inc. Revenue in Peripheral T-cell lymphoma Therapy Business (2019-2024) & (US$ Million)

Table 86. Spectrum Pharmaceuticals, Inc. Recent Development

Table 87. Celgene Corporation Company Detail

Table 88. Celgene Corporation Business Overview

Table 89. Celgene Corporation Peripheral T-cell lymphoma Therapy Product

Table 90. Celgene Corporation Revenue in Peripheral T-cell lymphoma Therapy Business (2019-2024) & (US$ Million)

Table 91. Celgene Corporation Recent Development

Table 92. Eisai Co., Ltd. Company Detail

Table 93. Eisai Co., Ltd. Business Overview

Table 94. Eisai Co., Ltd. Peripheral T-cell lymphoma Therapy Product

Table 95. Eisai Co., Ltd. Revenue in Peripheral T-cell lymphoma Therapy Business (2019-2024) & (US$ Million)

Table 96. Eisai Co., Ltd. Recent Development

Table 97. Leadiant Biosciences Company Detail

Table 98. Leadiant Biosciences Business Overview

Table 99. Leadiant Biosciences Peripheral T-cell lymphoma Therapy Product

Table 100. Leadiant Biosciences Revenue in Peripheral T-cell lymphoma Therapy Business (2019-2024) & (US$ Million)

Table 101. Leadiant Biosciences Recent Development

Table 102. Merck Company Detail

Table 103. Merck Business Overview

Table 104. Merck Peripheral T-cell lymphoma Therapy Product

Table 105. Merck Revenue in Peripheral T-cell lymphoma Therapy Business (2019-2024) & (US$ Million)

Table 106. Merck Recent Development

Table 107. Genmab AS Company Detail

Table 108. Genmab AS Business Overview

Table 109. Genmab AS Peripheral T-cell lymphoma Therapy Product

Table 110. Genmab AS Revenue in Peripheral T-cell lymphoma Therapy Business (2019-2024) & (US$ Million)

Table 111. Genmab AS Recent Development

Table 112. HUYABIO International Company Detail

Table 113. HUYABIO International Business Overview

Table 114. HUYABIO International Peripheral T-cell lymphoma Therapy Product

Table 115. HUYABIO International Revenue in Peripheral T-cell lymphoma Therapy Business (2019-2024) & (US$ Million)

Table 116. HUYABIO International Recent Development

Table 117. Research Programs/Design for This Report

Table 118. Key Data Information from Secondary Sources

Table 119. Key Data Information from Primary Sources

List of Figures

Figure 1. Global Peripheral T-cell lymphoma Therapy Market Size Comparison by Type (2024-2030) & (US$ Million)

Figure 2. Global Peripheral T-cell lymphoma Therapy Market Share by Type: 2023 VS 2030

Figure 3. Chidamide Features

Figure 4. Selinexor Features

Figure 5. Other Features

Figure 6. Global Peripheral T-cell lymphoma Therapy Market Size Comparison by Application (2024-2030) & (US$ Million)

Figure 7. Global Peripheral T-cell lymphoma Therapy Market Share by Application: 2023 VS 2030

Figure 8. Hospitals Case Studies

Figure 9. Clinics Case Studies

Figure 10. Peripheral T-cell lymphoma Therapy Report Years Considered

Figure 11. Global Peripheral T-cell lymphoma Therapy Market Size (US$ Million), Year-over-Year: 2019-2030

Figure 12. Global Peripheral T-cell lymphoma Therapy Market Size, (US$ Million), 2019 VS 2023 VS 2030

Figure 13. Global Peripheral T-cell lymphoma Therapy Market Share by Region: 2023 VS 2030

Figure 14. Global Peripheral T-cell lymphoma Therapy Market Share by Players in 2023

Figure 15. Global Top Peripheral T-cell lymphoma Therapy Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Peripheral T-cell lymphoma Therapy as of 2023)

Figure 16. The Top 10 and 5 Players Market Share by Peripheral T-cell lymphoma Therapy Revenue in 2023

Figure 17. North America Peripheral T-cell lymphoma Therapy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 18. North America Peripheral T-cell lymphoma Therapy Market Share by Country (2019-2030)

Figure 19. United States Peripheral T-cell lymphoma Therapy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 20. Canada Peripheral T-cell lymphoma Therapy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 21. Europe Peripheral T-cell lymphoma Therapy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 22. Europe Peripheral T-cell lymphoma Therapy Market Share by Country (2019-2030)

Figure 23. Germany Peripheral T-cell lymphoma Therapy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 24. France Peripheral T-cell lymphoma Therapy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 25. U.K. Peripheral T-cell lymphoma Therapy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 26. Italy Peripheral T-cell lymphoma Therapy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 27. Russia Peripheral T-cell lymphoma Therapy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 28. Nordic Countries Peripheral T-cell lymphoma Therapy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 29. Asia-Pacific Peripheral T-cell lymphoma Therapy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 30. Asia-Pacific Peripheral T-cell lymphoma Therapy Market Share by Region (2019-2030)

Figure 31. China Peripheral T-cell lymphoma Therapy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 32. Japan Peripheral T-cell lymphoma Therapy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 33. South Korea Peripheral T-cell lymphoma Therapy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 34. Southeast Asia Peripheral T-cell lymphoma Therapy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 35. India Peripheral T-cell lymphoma Therapy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 36. Australia Peripheral T-cell lymphoma Therapy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 37. Latin America Peripheral T-cell lymphoma Therapy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 38. Latin America Peripheral T-cell lymphoma Therapy Market Share by Country (2019-2030)

Figure 39. Mexico Peripheral T-cell lymphoma Therapy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 40. Brazil Peripheral T-cell lymphoma Therapy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 41. Middle East & Africa Peripheral T-cell lymphoma Therapy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 42. Middle East & Africa Peripheral T-cell lymphoma Therapy Market Share by Country (2019-2030)

Figure 43. Turkey Peripheral T-cell lymphoma Therapy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 44. Saudi Arabia Peripheral T-cell lymphoma Therapy Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 45. Antengene Revenue Growth Rate in Peripheral T-cell lymphoma Therapy Business (2019-2024)

Figure 46. Genor BioPharma Co., Ltd. Revenue Growth Rate in Peripheral T-cell lymphoma Therapy Business (2019-2024)

Figure 47. Hospira (Pfizer Inc.) Revenue Growth Rate in Peripheral T-cell lymphoma Therapy Business (2019-2024)

Figure 48. Dizal Pharma Revenue Growth Rate in Peripheral T-cell lymphoma Therapy Business (2019-2024)

Figure 49. Bristol-Myers Squibb Company Revenue Growth Rate in Peripheral T-cell lymphoma Therapy Business (2019-2024)

Figure 50. Sigma-Tau Pharmaceuticals, Inc. Revenue Growth Rate in Peripheral T-cell lymphoma Therapy Business (2019-2024)

Figure 51. Pacira Pharmaceuticals, Inc. Revenue Growth Rate in Peripheral T-cell lymphoma Therapy Business (2019-2024)

Figure 52. Spectrum Pharmaceuticals, Inc. Revenue Growth Rate in Peripheral T-cell lymphoma Therapy Business (2019-2024)

Figure 53. Celgene Corporation Revenue Growth Rate in Peripheral T-cell lymphoma Therapy Business (2019-2024)

Figure 54. Eisai Co., Ltd. Revenue Growth Rate in Peripheral T-cell lymphoma Therapy Business (2019-2024)

Figure 55. Leadiant Biosciences Revenue Growth Rate in Peripheral T-cell lymphoma Therapy Business (2019-2024)

Figure 56. Merck Revenue Growth Rate in Peripheral T-cell lymphoma Therapy Business (2019-2024)

Figure 57. Genmab AS Revenue Growth Rate in Peripheral T-cell lymphoma Therapy Business (2019-2024)

Figure 58. HUYABIO International Revenue Growth Rate in Peripheral T-cell lymphoma Therapy Business (2019-2024)

Figure 59. Bottom-up and Top-down Approaches for This Report

Figure 60. Data Triangulation

Figure 61. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

RELATED REPORTS

Global Microwave Tumor Ablation System Market Research Report 2024

120 Pages

Type: Report

Code: QYRE-Auto-22N12035

Fri Oct 04 00:00:00 UTC 2024

Add to Cart

Global Carbon Fiber Radiotherapy Table Top and Headrest Market Research Report 2024

120 Pages

Type: Report

Code: QYRE-Auto-1S13226

Thu Aug 29 00:00:00 UTC 2024

Add to Cart

Global Multi-target MET TKIs Market Research Report 2024

120 Pages

Type: Report

Code: QYRE-Auto-9X18229

Wed Aug 28 00:00:00 UTC 2024

Add to Cart

Global MET TKIs Market Research Report 2024

120 Pages

Type: Report

Code: QYRE-Auto-32L18018

Wed Aug 28 00:00:00 UTC 2024

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions